Podcasts about Abiomed

Teaching best practices for transporting Impella patients is something Zac Bunzey handles every day. As a clinical education manager at Life Flight Network, Zac joins Shane Turner to share how targeted training campaigns, hands-on experience, and tools like the Impella app, combined with Abiomed's 24/7 support, have markedly boosted crew confidence and proficiency.Plus, you'll learn about the importance of cognitive aids and routine practice with low-frequency events to maintain skills. Whether you're experienced in Impella transports or new to the process, this episode offers crucial strategies to enhance your crew's readiness and effectiveness in managing these critical patients.In this episode:Shane Turner, RN, CFRN, NRP, FP-C, CMTE, Chattanooga, TNZac Bunzey, Clinical Education Manager, Life Flight Network

CardioNerds Critical Care Cardiology Council members Dr. Gurleen Kaur and Dr. Katie Vanchiere meet with Dr. Yash Patel, Dr. Akanksha, and Dr. Mohammed El Nayir from Trinity Health Ann Arbor. They discuss a case of pulmonary air embolism, RV failure, and cardiac arrest secondary to an ocular venous air embolism. Expert insights provided by Dr. Tanmay Swadia. Audio editing by CardioNerds Academy intern, Grace Qiu. A 36-year-old man with a history of multiple ocular surgeries, including a complex retinal detachment repair, suffered a post-vitrectomy collapse at home. He was found hypoxic, tachycardic, and hypotensive, later diagnosed with a pulmonary embolism from ocular venous air embolism leading to severe right heart failure. Despite a mild embolic burden, the cardiovascular response was profound, requiring advanced hemodynamic support, including an Impella RP device (Abiomed, Inc.). Multidisciplinary management, including fluid optimization, vasopressors and mechanical support to facilitate recovery. This case underscores the need for early recognition and individualized intervention in cases of ocular venous air embolism. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls- Clear Vision, Clouded Heart: Ocular Venous Air Embolism with Pulmonary Air Embolism, RV Failure, and Cardiac Arrest Hypoxia, hypotension and tachycardia in a patient following ocular instrumentation are classic findings suggestive of pulmonary embolism from possible air embolism. The diagnosis of RV failure is based on clinical presentation, echocardiographic findings (such as McConnell's sign), and invasive hemodynamic assessment via right heart catheterization. Mechanical circulatory support can be considered as a temporary measure for patients with refractory RV failure. Central Figure: Approach to Pulmonary Embolism with Acute RV Failure Notes - Clear Vision, Clouded Heart: Ocular Venous Air Embolism with Pulmonary Air Embolism, RV Failure, and Cardiac Arrest 1. What is an Ocular Venous Air Embolism (VAE), and how can it be managed in critically ill patients? An Ocular Venous Air Embolism is defined as the entry of air into the systemic venous circulation through the ocular venous circulation, often during vitrectomy procedures. Early diagnosis is key to preventing cardiovascular collapse in cases of Ocular Venous Air Embolism (VAE).  The goal is to stop further air entry. This can be done by covering the surgical site with saline-soaked dressings and checking for air entry points. Adjusting the operating table can help, especially with a reverse Trendelenburg position for lower-body procedures. The moment VAE is suspected, discontinue nitrous oxide and switch to 100% oxygen. This helps with oxygenation, speeds up nitrogen elimination, and shrinks air bubbles. Hyperbaric Oxygen Therapy can reduce bubble size and improve oxygenation, especially in cases of cerebral air embolism, when administered within 6 hours of the incident. Though delayed hyperbaric oxygen therapy can still offer benefits, the evidence is mixed. VAE increases right heart strain, so inotropic agents like dobutamine can help boost cardiac output, while norepinephrine supports ventricular function and systemic vascular resistance, but this may also worsen pulmonary resistance.  Aspiration of air via multi-orifice or Swan-Ganz catheters has limited success, with success rates ranging from 6% to 16%. In contrast, the Bunegin-Albin catheter has shown more promise, with a 30-60% success rate. Catheterization for acute VAE-induced hemodynamic compromise is controversial, and there's insufficient evidence to support its ...

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Cardiogenic shock is a devastating condition with a persistent 50% mortality rate. However, groundbreaking treatments and technologies are now dramatically improving survival odds. Join Shane Turner as he sits down with Jason Weatherly, Cardiogenic Shock Commercial Marketing Manager at Abiomed, to explore these advancements and the life-saving impact of the Impella device.Jason highlights the recent DanGer Shock RCT, which confirmed that Impella CP® with SmartAssist® improves survival by 12.7%. Together, they delve into how these medical breakthroughs are crucially linked to critical care transport, emphasizing innovative strategies that are essential for enhancing patient outcomes and shaping the future of cardiogenic shock treatment.In this episode:Shane Turner, RN, CFRN, NRP, FP-C, CMTE, Chattanooga, TNJason Weatherly, Cardiogenic Shock Commercial Marketing Manager at Abiomed

Collaboration plays a vital role in setting new benchmarks in cardiac transport. Join Shane Turner as he talks with Bill Hallinan, regional clinical manager for Abiomed, about integrating pre-hospital and hospital care to enhance outcomes for patients experiencing cardiogenic shock. With decades of experience in firefighting, nursing and transport, Bill shares his invaluable insights and vision for the future of cardiac care.Shane and Bill emphasize the critical importance of early recognition of cardiogenic shock, and the need for effective communication and respect among providers. They also discuss the unique challenges and opportunities in pre-hospital and transport care. Plus, you'll learn why clear definitions and standards for cardiac recovery centers are crucial, and how standardized protocols and technological innovations can dramatically improve patient outcomes. In this episode:Shane Turner, RN, CFRN, NRP, FP-C, CMTE, Chattanooga, TNBill Hallihan, RN BSN, Regional Clinical Manager, Abiomed

Maquet Cardiovascular LLC v. Abiomed Inc.

Send us a textIn the fifth episode of How to Accelerate the Speed of Engineering, host Aaron Moncur interviews Jim Gabriel. Jim shares his insights on overcoming common bottlenecks, effective decision-making, fostering psychological safety, cross-functional collaboration, data-driven performance improvement, and lessons learned from attempts to expedite engineering processes.Main Topics:Identifying and addressing bottlenecks in engineering projectsEmpowering teams to make effective decisionsBalancing autonomy and guidance for engineersFailing fast and failing cheap to drive innovationThe role of leadership in creating a culture of accelerationStrategies for enhancing cross-functional collaborationLeveraging data and metrics to improve team performanceIntroducing new technologies and tools to streamline engineeringUnconventional approaches to expedite engineeringEnhancing communication and meeting effectivenessLessons learned from attempts to accelerate engineeringAbout the guest: Jim Gabriel is a seasoned engineering leader whose most recent expertise lies in the medical device industry. As the Associate Director of Engineering at Abiomed, he played a crucial role in leading teams focused on the development of cutting-edge heart pump technologies that save lives. Jim holds a Bachelor's degree in Industrial and Manufacturing Engineering from Western Michigan University and a Master's degree in Engineering Management from Northeastern University.Links:Jim Gabriel - LinkedInArchangel Operations WebsiteAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Welcome to Abiomed's Quarterly Update, where education is at the forefront. In this episode, host Shane Turner is joined by Jena Billig, primary trainer for the West region, to dive into the intricacies of the Impella pump's heparin-free purge system.Jena provides a comprehensive understanding while addressing misconceptions. She explains the importance of using a dextrose and water-based purge solution with heparin or sodium bicarb additive to prevent blood proteins from accumulating in the pump motor housing. Plus, Shane and Jena explore new features of the Impella Five, gen two catheter, designed to enhance safety for transport providers, including the intuitive catalog system and three-point fixation method.Whether you're a seasoned provider or new to the field, this episode offers valuable insights to improve patient care and transport practices. Tune in now to stay informed and elevate your knowledge of the Impella device and purge system!In this episode:Shane Turner, RN, CFRN, NRP, FP-C, CMTE, Chattanooga, TNJena Billig, BSN, RN, CCRN, CFRN, Idaho Springs, Colorado

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA recently approved a biosimilar of Stelara from Alvotech and Teva, set to launch early next year. Johnson & Johnson reported mixed sales performance for new multiple myeloma drugs, with Tecvayli sales exceeding expectations and Carvykti underperforming. Roche also released survival data for a new lymphoma drug, potentially giving it an edge over a competitor. The US government sued Regeneron for allegedly falsely reporting prices on the blockbuster eye drug Eylea. Other topics covered in the newsletter include drug pricing trends, diversity in clinical trials, and the weight loss drug market.In order to successfully execute health advertising campaigns, marketers need to take a proactive approach by targeting health audience segments online. Actionable insights are provided to maximize the impact of media investment through tips such as implementing a test and learn strategy, scaling results quickly, and asking tough questions to potential health targeting partners. Veeva Crossix is highlighted as a company that implements these tactics to reach consumers throughout the patient journey.Abbott CEO Robert Ford highlighted new and upcoming products during an earnings call, emphasizing the recently approved Triclip valve as a significant opportunity for growth. The FDA issued a warning to Soulaire for selling a device outside of authorized uses. Lilly's obesity drug showed benefits in a sleep disorder study, indicating potential new uses. Johnson & Johnson's $30 billion spending spree on companies like Abiomed, Laminar, and Shockwave Medical may continue. Additionally, Philips entered into a consent decree with the FDA, where the agency will use rare powers to require repairs, replacements, or refunds for recalled respiratory machines.Eli Lilly's weight-loss drug Zepbound has shown effectiveness in treating sleep apnea, leading the company to prepare for a label expansion. Amylyx faced a setback with the failure of its ALS drug Relyvrio, leading to layoffs and market withdrawal. Despite this, the company saw success in treating Wolfram syndrome. Sage Therapeutics also announced the discontinuation of its Parkinson's disease program after disappointing results in phase II trials, shifting focus to Huntington's and Alzheimer's diseases.The medical device industry is increasingly incorporating AI and digital health technologies to improve performance and outcomes. Overall, the medtech sector is evolving rapidly with new products and technologies driving growth and innovation.

What makes us tick? Join Shane Turner and the Abiomed transport team as they share the driving forces behind their dedication to training. From simplifying complex issues to empowering transport crews, Transport Talks is here to help you feel more confident and, ultimately, to buoy patient outcomes. Let Transport Talks be your companion as you focus on what truly matters: patient recovery and saving lives beyond the hospital walls.In this episode, hear from members of Abiomed's Critical Care Transport training team:Diana Draehn, RN, BSN, CFRN, LP, Dallas, TXJena Billig, BSN, RN, CCRN, CFRN, Denver, COCaleb Merrell, RN, BSN, CFRN, LP, Austin, TXShane Turner, RN, CFRN, NRP, FP-C, CMTE, Chattanooga, TNNPS-4297

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Orchard gene therapy wins first FDA nod for rare pediatric disease The bad — Abiomed recalls heart pump instructions due to perforation risks  The ugly — J&J files lawsuit against a former employee for allegedly taking over 1,000 files to Pfizer

As members of Abiomed's Critical Care Transport Team, we know that every transport is a lifeline, and every moment counts in our mission to recover hearts and save lives. Inside Impella: Transport Talks is a podcast where we equip you with knowledge and confidence as you transport Impella patients. Subscribe now for monthly episodes offering best practices, valuable lessons, and camaraderie. Let us be your companion as you focus on what truly matters: patient recovery and saving lives beyond the hospital walls.

The DoD launched a pilot program in 2011 called SkillBridge. The intention of the program is to provide service members and spouses with an in-depth and real-world training opportunity as they prepare to move from active duty to post-military employment. Today, the program has grown to almost 3,000 different SkillBridge opportunities. Cameron-Brooks is one of them! So what is the Cameron-Brooks SkillBridge experience like? It's the ideal opportunity for high-achieving JMOs that want to transition to a growth position in business. Cameron-Brooks has been an approved DoD SkillBridge provider since 2022 and many officers have participated in our 12-week, curated training program as they prepare to attend the Cameron-Brooks Career Conference and follow-up interview process. What can come from a Cameron-Brooks SkillBridge opportunity? Lots more opportunity! In this episode, I talk to Wyatt Boyd. Wyatt shares his Cameron-Brooks SkillBridge experience in preparation for the January 2023 Career Conference. At the conference, he interviewed with 10 industry-leading companies, and just about every one of them demonstrated a high level of interest in pursuing him for follow-up interviews. Wyatt conducted multiple follow-up interviews and received offers for employment along the way. He ultimately received and accepted an offer with Abiomed, a Johnson and Johnson company. Wyatt describes how he was able to benefit from the Cameron-Brooks SkillBridge program in order to maximize his opportunities, earn multiple offers for employment, and ultimately select the opportunity that best matched his career goals. So, what does Wyatt attribute to his success? In a phrase: Preparation is the Key to Success Wyatt was able to focus on some key areas while on the SkillBridge, including: Development and Preparation Program (DPP©) Tabs and Modules: This 5-tab curriculum is designed to lead the participant through a thorough self-analysis, business skill development, in-depth career field option research, and interview answer construction. Development and Preparation Program (DPP©) Required Reading Program: This 10-book reading program is designed to educate and inform the participant on crucial business concepts such as Lean/Six Sigma, Project Management, Corporate Finance, Data Analysis, Business to Business Selling, Operational Excellence, Rapport Building, Team Leadership and other important business concepts. Resume Creating Guidelines – This tool, in conjunction with a proprietary pre-formatted Microsoft Word template, is designed to guide the participant through a resume creation process in preparation for business interviews. Interview Skills Workshops – The participant will participate in 3 different levels of an Interview Skills Workshop: - Basic Interview Skills Workshop: This workshop is designed to teach the fundamentals of interviewing, including how to build rapport, connect their military background, and the methods to answering the 28 most commonly asked interview questions. - Intermediate Interviews Skills Workshop: This workshop is designed to continue to instill the fundamentals of interviewing while allowing the participant to practice their interview skills under the supervision of a trained Transition Coach. - Advanced Interview Skills Workshop: This workshop is typically provided in a smaller setting (4-5 participants) in order to allow the candidate to practice advanced interview skills like answering less common questions, asking quality questions, and closing the interview. Career Field Media: This resource is primarily comprised of seven 1-hour videos designed to educate the participant on the 4 major categories of career fields that Junior Military Officers typically pursue: Engineering Management, Team Leadership, Business Analysis, and Business-to-Business Sales. Interview Preparation Workshops: This workshop, in conjunction with the proprietary Interview Guideline Worksheet,

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, January 24, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Cognito Therapeutics has enrolled its first patients in a sensory neurostim biomarker study. Fast Five hosts Sean Whooley and Danielle Kirsh discuss what the trial will look like and how executives see this transforming treatment option. The UK NHS Trust treated the first patients with Allurion's weight loss balloon. Learn more about the technology and the results from the first treatments. A former Boston Scientific executive joined the board of directors of pulsed field ablation company Mirai Medical. Whooley talks about their career history and what Mirai Medical is doing. Earnings season is upon us, and Johnson & Johnson MedTech has reported a 13% sales uptick in Q4. Hear more updates from the Abiomed acquisition and how the company's electrophysiology portfolio is doing. A new report claims that Samsung is joining Apple in the non-invasive glucose monitor battle. The Fast Five hosts talk about the implications this could have on the glucose monitoring market and if there's a projected timeline. BONUS: How does medtech CEO compensation compare? Read more about the pay dynamics of the medical device industry.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Fluid restriction, bed rest, leg compression in acute heart failure Device-detected atrial fibrillation Snapshots  Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Biykem Bozkurt and Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1142 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Biykem Bozkurt has declared to have potential conflicts of interest to report: consulting for Abbott, Abiomed, American Regent, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Paulus Kirchhof has declared to have potential conflicts of interest to report: fees from AstraZeneca, Roche Diagnostics, Johnson&Johnson, Philips, Medtronic, Boehringer-Ingelheim, Daiichi Sankyo. Research fundings from Sanofi Adventis, Abbott, German Ministry of Education and Research (BMBF), Daiichi Sankyo, British Heart Foundation, Leducq Foundation, European Union horizon2020, UK Medical Research Council and NIHR (UK National Institute of Health Research). Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Kaiser Permanente and unions have reached a "tentative agreement" on new contract terms for 75,000 healthcare workers following a three-day strike. UnitedHealth has raised its guidance and beat Q3 expectations due to stabilizing medical loss ratio (MLR), although costs could rise in Q4. UnityPoint Health and Presbyterian Healthcare Services have called off their cross-market merger due to financial woes and the departure of key executives. Elevance, formerly known as Anthem, has confirmed "adjustments" to resources as employees report job cuts. Rene Quashie, an executive at the Consumer Technology Association, believes that artificial intelligence (AI) could revolutionize the healthcare industry, but regulation and guardrails are needed. NextGen Healthcare has unveiled an AI notetaking product called Ambient Assist Tool, which provides notes for clinician review within 30 seconds of a completed patient encounter.The FDA is establishing a Digital Health Advisory Committee to gain insights into the benefits, risks, and outcomes associated with digital technologies in healthcare.In 2024, there are several top medtech conferences planned that will cover topics such as new technologies in diabetes, cardiology, orthopedics, and more.The FDA has also prioritized guidance on artificial intelligence (AI), cybersecurity, and pulse oximeters for the upcoming financial year, adding 18 draft documents to its list of priorities.GE Healthcare has won a $44 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop an AI-enabled ultrasound system.The European Commission has ordered Illumina to divest its subsidiary Grail, with an undisclosed timeline and potential additional fines. Illumina believes that the commission does not have jurisdiction over the completed merger.J&J's Abiomed has received a warning letter from the FDA regarding quality system problems in a group of recalled devices and the requirement for premarket authorization for the monitoring software used with the impella heart pump.The adoption of AI in medtech has prompted discussions about industry regulations, data collection, and the potential for patient treatment and outcomes.

Title: Cardiology Grand Rounds: Cerebral Protection for TAVR Evidence and Rationale Speaker: Alexandra Lansky, MD Professor of Medicine, Section of Cardiology Yale School of Medicine Disclosures: Grant/Research: Emboline, Emblok, Boston Scientific Consultant: MedAlliance, Abiomed, Boston Scientific Objectives: - To review the incidence of stroke after TAVR - To review the timing and mechanisms of stroke after TAVR - To review the evidence for Cerebral Embolic Protections - To review future innovations in cerebral embolic protection

Anika Therapeutics received the final FDA 510(k) clearance for its Integrity implant system for improving outcomes in rotator cuff repair procedures through biologic healing. The hyaluronic acid-based patch augments an injured tendon, promoting rotator cuff healing. Fast Five hosts Sean Whooley and Danielle Kirsh delve into how the device works and what the regulatory nod means for Anika. Ventricular assist devices save lives and another one may soon be entering the fold. MagAssist won FDA breakthrough device designation for its NyokAssist VAD, which provides mechanical circulatory support for high-risk percutaneous interventions. Find out what led the agency to grant this designation. Axonics will soon have a new chief financial officer after longtime executive Dan Dearen notified the company of his intent to retire. The company already picked a replacement, promoting from within to fill the role. Learn more about Axonics' selection and what the new executive brings to the company in terms of experience and know-how. In another executive change, Tandem Diabetes Care announced that its chief commercial officer plans to resign from the role. Brian B. Hansen had been the company's CCO since 2016. Whooley and Kirsh take a look at Hansen's background and the terms of a separation agreement struck between Hansen and the automated insulin delivery technology developer. For the third time in as many months, Abiomed issued a correction for its Impella heart pumps. The FDA Class I recall pertains to the instructions for use for the system. The hosts break down the numbers behind this recall and what kind of mitigations Abiomed is implementing to remedy the issue. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Edge-to-edge mitral valve repair The future treatment of chronic heart failure Mythbusters: Is chocolate healthy for the heart? Host: Susanna Price Guests: Carlos Aguiar, Milton Packer and Stephan Windecker Want to watch that episode? Go to: https://esc365.escardio.org/event/1122   Disclaimer This programme is supported by Siemens Healthineers in the form of an educational grant. The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Milton Packer and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme. Stephan Windecker has declared to have potential conflicts of interest to report: payments from Amgen and Medtronic, research funding from Abbott, Amgen, AstraZeneca, Bayer AG, Biotronik, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Guerbet AG, Johnson & Johnson, Medtronic, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi Adventis, V-Wave, Abiomed, Boehringer-Ingelheim, Bristol Myers Squibb, B.Braun, Cordis Medical, Miracor medical, Pharming Tech, CSL Behring, Farapulse Inc., Fumedica, Idorsia, Inari Medical, MedAlliance.

AdvaMed President and CEO Scott Whitaker sits down for a wide-ranging discussion with Michael Minogue, former Chairman, President, and CEO of Abiomed. The lively conversation, encompassing Minogue's military career to his decades of work in the medtech industry, highlights his entrepreneurial work ethic, leadership values, the lifesaving innovation the medtech industry is responsible for, and the ongoing work to help transitioning servicemembers find meaningful careers in the health care industry.

Abbott has now seen two quarters in a row of double-digit organic sales growth in its underlying business. Now the company is betting on its productive, innovative pipeline to build momentum. Fast Five hosts Sean Whooley and Danielle Kirsh go over the full performance of the company and how each of its segments performed. Johnson & Johnson MedTech posted revenues of $7.9 billion, marking a 12.9% improvement year-over-year. Learn what the growth drivers were for the MedTech segment and what analyst's think about the second-quarter results.  The initiation of Magnus Medical's neurostim trial marks a significant milestone in the field of mental health treatment, offering hope for patients with treatment-resistant depression. Whooley and Kirsh discuss the company's technology and the potential impact it could have on the treatment of treatment-resistant depression.  MediView XR announced this week that it received FDA 510(k) clearance for its XR90 augmented reality-based visualization and navigation platform. Find out the purpose of the AR platform and how it works to address the limitations of traditional medical imaging technologies. Johnson & Johnson's Abiomed unit issued another recall for some of its Impella heart pumps. The recall is for TAVR-related devices. Whooley explains the reason for the recall, the risks involved and provides comments from Abiomed on the situation.  Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Sparrow BioAcoustics' FDA clearance for their smartphone stethoscope marks a significant advancement in remote patient monitoring and telehealth. This innovative technology allows healthcare professionals to capture and analyze heart and lung sounds using a smartphone, enabling more accessible and convenient monitoring of patients' respiratory health. Fast Five hosts Sean Whooley and Danielle Kirsh have all the details. The FDA clearance of GE Healthcare's Sonic DL AI technology for expediting MRI scans is another significant breakthrough in medical imaging. This platform could enable new imaging paradigms, including high-quality cardiac MRI in a single heartbeat. Whooley explains how the technology works and what this could mean for cardiac imaging and healthcare. Masimo's FDA clearance of its vital sign monitor highlights the importance of telehealth in today's healthcare settings. This wearable device provides continuous monitoring of key vital signs, such as heart rate, oxygen saturation, and respiratory rate, enabling healthcare professionals to track patients' health parameters outside of traditional clinical settings. Kirsh and Whooley discuss the technology and how it works.  Novo Nordisk's potential acquisition of a majority stake in BioCorp demonstrates the growing interest of pharmaceutical companies in digital health solutions. It follows Bayer's announcement last week that it was making a move to digital health. Whooley explains the financial details of the deal and how optimistic executives are at both companies. Abiomed's recall of certain Impella 5.5 with SmartAssist devices is an important step in ensuring patient safety and maintaining quality standards. Product recalls are a vital aspect of post-market surveillance and risk management, aiming to address any potential issues that may arise with medical devices. The Fast Five hosts share the details of the recall, including how many devices are affected and if there have been any reported complaints related to the device. Check out the show notes at MassDevice.com/podcast.

Johnson & Johnson beat earnings expectations in the final quarter of 2022 even as a strong dollar and sinking COVID-19 vaccine sales hurt revenue. The healthcare giant also debuted a better-than-expected 2023 earnings forecast. J&J said fourth-quarter earnings slipped 26% to $3.52 billion and revenue declined 4.4% to $23.71 billion. Sales were hurt last year by the strong U.S. dollar, which is currently worth more than a euro. That can affect companies with a lot of international business because they have to convert those sales into dollars when they report earnings. J&J brings in nearly half of its revenue from outside the United States. The company's international sales fell more than 11% in the quarter, but that decline was only 1% when not counting exchange rates. J&J also recorded no U.S. sales in the quarter from its one-shot COVID-19 vaccine, which brought in $689 million in revenue from international markets. U.S. regulators have strictly limited who can receive J&J's shot due to a small risk of rare but serious blood clots. Johnson & Johnson sells prescription drugs and medical devices. It is splitting off its consumer health business, which includes well-known products like BandAids. Chairman and CEO Joaquin Duato said that separation should be completed this year. Revenue from pharmaceuticals, the company's largest business, fell 7% to $13.16 billion in the fourth quarter even as worldwide sales of the cancer treatment Darzalex soared nearly 27% to more than $2 billion. Medical device revenue slipped 1% to about $6.8 billion. J&J also brought in $3.8 billion in sales from consumer health. The company booked costs in the quarter from winding down COVID-19 vaccine production, splitting off consumer health, and completing its acquisition of cardiovascular technology company Abiomed, a deal it announced in November. Overall, adjusted earnings totaled $2.35 per share in the fourth quarter. Analysts expected earnings of $2.23 per share on $23.9 billion in revenue, according to FactSet. This article was provided by The Associated Press.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Cardiac involvement in Fabry's Disease Anti-thrombotic therapy post PCI: DAPT in 2023  Mythbusters: Powernap for heart health Host: Rick Grobbee Guests: Perry Elliott, Nicolle Kraenkel, Roxana Mehran and Franz Weidinger Want to watch that episode? Go to: https://esc365.escardio.org/event/896 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes.  The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.  Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests  Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Franz Weidinger have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.  Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.  Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Sanofi. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll;  personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, WebMD; Equity

In this episode, your diligent team of DeviceTalkers - Executive Editor Chris Newmarker, Pharma Editor Brian Buntz, Managing Editor Jim Hammerand, Senior Editor Danielle Kirsh, Associate Editor Sean Whooley and DeviceTalks Editorial Director Tom Salemi – assembled to review our Top 10 events, trends and newsmakers. We've got some highs – robots, diabetes – and some lows – Supply Chain, CPAP machines – and a whole lot of interesting things right in between. All an all, we're bullish on what's to come in 2023! And we only mentioned Covid-19 once. Companies mention include Abbott, Abiomed, Ambu, Becton Dickinson, Boston Scientific, CMR Surgical, Dexcom, Endiatx, embecta, Intuitive, Johnson & Johnson Medtech, Medtronic, Neuralink, Philips, Senseonics, Stryker, Synchron, Vicarious Surgical, Zimmer Biomet, ZimVie, and many more. Thank you for listening to the DeviceTalks Weekly Podcast. Subscribe to this podcast on any major podcast player.

In this episode, Celine Martin, company group chairman, Cardiovascular & Specialty Solutions Group, offers insights from her career at Johnson & Johnson. What are the four variables you need to consider to thrive in a global company. Martin also shares insights on cardiac ablation, neurovascular, and where the company is headed following the acquisition of Abiomed. Paul Grand, CEO of Medtech Innovator, joins as a co-host offering insights on Chris Newmarker's Newsmakers – Moon Surgical, Butterfly Network, Medtronic, Avail Medsystems, Dexcom, and Fresenius Medical. Grand shares a personal connection to one of the companies. Grand, Newmarker and Tom Salemi also share their thoughts on the retirement of Mike Mussallem, CEO of Edwards Lifesciences. Thank you to Nordson Medical for sponsoring this episode. Go to NordsonMedical.com for more information. Thank you for listening to the DeviceTalks Weekly Podcast You can subscribe to this podcast on any major podcast player.

Advertisers bail from Twitter after Elon takes the reins, J&J makes an acquisition to fuel more growth, and The Fed raised interest rates another 75bps. October 27 - November 3 #stocks #finance #news ----- 00:00 Intro 00:52 Elon & Twitter 10:06 Amazon pauses hiring, Stripe fires 13:15 J&J buys Abiomed 16:48 Fed rate hike 20:05 Leave your thoughts ----- IPG: https://www.cnbc.com/2022/11/01/ad-giant-ipg-advises-brands-to-pause-twitter-spending.html Elon: https://twitter.com/elonmusk Chartrdaily: https://www.instagram.com/p/CkgOK9cOJEV/ Firing: https://www.cnbc.com/2022/11/02/twitter-reportedly-ready-to-cut-about-3700-employees.html Amazon: https://www.cnbc.com/2022/11/03/amazon-pauses-hiring-for-corporate-workforce.html Stripe: https://www.cnbc.com/2022/11/03/stripe-plans-to-lay-off-14percent-of-workers.html J&J: https://www.cnbc.com/2022/11/01/johnson-johnson-to-buy-abiomed-in-16point6-billion-deal.html Fed hike: https://www.wsj.com/livecoverage/federal-reserve-meeting-interest-rate-hike-november-2022 ----- Website- https://jemi.so/financialfriends

En plena temporada de resultados comentamos algunos detalles que nos han llamado la atención en las presentaciones de resultados. Comentamos los resultados de Prologis, PPG industries, META, GOOG, REE y Abiomed.

Two of Australia's biggest betting agencies, Sportsbet and Bet365, may face multimillion-dollar fines following after an audit authorised by Australia's financial crime watchdog.   Airbnb has broken one of its own financial records after a huge northern hemisphere summer… but now, investors are little more concerned about its prospects.   Johnson & Johnson is buying a heart device maker named Abiomed for around $17B USD in its biggest deal in almost six years.   ---   Build the financial wellbeing of your team with Flux at Work: https://bit.ly/fluxatwork Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance   ---   The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.See omnystudio.com/listener for privacy information.

VW teilt keine Autos mehr, Airbnb teilt in Zukunft zu wenige Unterkünfte und Uber teilt mehr Fahrten als je zuvor. Außerdem pusht China die Börsen, das iPhone pusht Sony und die Übernahme durch Johnson & Johnson pusht Abiomed. Selbst in Krisenzeiten wird Bier gekauft. Constellation Brands (WKN: 871918) hat Corona und freut sich. Was sind die beliebtesten ETFs Deutschlands? Zu den größten gehören: Bloomberg SASB U.S. Corporate ESG USD ETF (WKN: A2QB0R), Core S&P 500 USD ETF (WKN: A0YEDG), Physical Gold USD ETC (WKN: A1KWPQ), FTSE All-World USD ETF (WKN: A1JX52) & Semiconductor USD ETF (WKN: A2QC5J). Diesen Podcast der Podstars GmbH (Noah Leidinger) vom 02.11.2022, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

Jay Powell will probably hammer the dovish hopes, and the latest risk rally when he speaks following the FOMC decision today. In preparation for an unpleasantly hawkish Fed statement today, the US 3-month yield spiked above the 4.20% mark, the level it was normally supposed to be in 18 months, the 2-year yield returned above the 4.50% mark, the US dollar index advanced and the US equities sold off, as yields jumped. The ADP report is due a couple of hours before the Fed decision, and is expected to have eased below 200'000 in October. Any positive surprise will likely further boost the Fed hawks, and dampen the mood in risk assets. In China, stocks extend gains on an unverified social media post that China will end its Covid measures. The Chinese foreign ministry spokesman said he was unaware of the plan. Disneyland in Shanghai was shut with people in it, after a Covid case was found in the park… I wouldn't cry victory just yet! In Britain, the first day of bond selling from the Bank of England was a success. The BoE sold 1$750 million worth of bonds, demand exceeded offer, gilt yields pulled lower and sterling was steady. Airbnb fell 5% post-market on disappointing Q4 outlook, Sony jumped near 10% in NY as softer yen helped boosting sales, BP announced the second biggest quarterly results, while Abiomed jumped 50% after Johnson & Johnson announced to buy the company. Listen to find out more!

A 50% premium is a buyout price most investors would love to see. To acquire Abiomed, Johnson & Johnson was happy to pay it.   (0:17) Bill Mann discusses: - Why he believes a "shock and awe" price was worth paying for J&J - How Abiomed strengthens the company's medical device portfolio - Amazon expanding its ad-free music library for Prime members - Signs that the retail giant is gunning for Spotify, Disney, and other entertainment companies   (10:33)  Alison Southwick and Robert Brokamp discuss how shortcuts can make you a smarter saver.   Companies discussed: JNJ, ABMD, AMZN, SPOT, DIS, PARA   Host: Chris Hill Guest: Bill Mann, Alison Southwick, Robert Brokamp Producer: Ricky Mulvey Engineers: Tim Sparks, Rick Engdahl

Plus: Shares of Abiomed rise 50% after Johnson & Johnson announces plan to buy the company. Airbnb shares fall 4% after hours after reporting higher revenue but lower-than-expected number of nights booked by travelers. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber explored what investors can expect from the markets in November after a bullish October, which included the Dow's best month since January 1976. M&A also in the spotlight: Shares of Abiomed soaring after Johnson and Johnson agreed to acquire the cardio technology company in a deal valued at $16.6 billion. The anchors also discussed Chinese stocks in rally mode. Unverified posts on social media said policymakers in China are looking to relax stringent COVID rules. Also in focus: Day one of the Fed's policy meeting, President Biden accuses big oil companies of "war profiteering" and backs the idea of slapping them with a windfall tax, plus market reaction to earnings from the likes of Pfizer, Eli Lilly and Uber.

Investi come me:https://www.patreon.com/cambiaretuttoIl sito: https://www.swingtradingitalia.comIl gruppo:https://www.facebook.com/groups/244662280228532/Il mio profilo:https://www.facebook.com/cambiare.tutto.56mail:cambiaretuttocambiaresubito@gmail.comNB: In nessun modo il mio contenuto audio e/o video vuole essere una sollecitazione all'acquisto o vendita.

In this episode of The Mentors Radio, Host Tom Loarie talks with best-selling author and Harvard Career Advisor Gorick Ng about what he wishes he had known when starting college and before his last year in college. This is a show for students and also for their parents, grandparents and for school counselors. Gorick specializes in coaching first-generation, low-income students. His best-seller book is titled Unspoken Rules: Secrets in Starting Your Career Off Right. Gorick's advice is well-worth a listen!!! Find Show Notes below. Listen to this episode below (after the first broadcast Saturday) and Never Miss an Episode by subscribing HERE to listen to the post-airing podcast on any podcast platform, on Any device!!! (click here) SHOW NOTES: GORICK NG is the Wall Street Journal Bestselling Author of The Unspoken Rules: Secrets to Starting Your Career Off Right, a book published by Harvard Business Review Press named by Thinkers50 as one of the top 10 management books of 2022. It is a guide to help early career professionals, especially those from underrepresented backgrounds, navigate the school-to-work transition and ascend to positions of leadership, based on 500+ interviews with professionals across geographies, industries, and job types. The Unspoken Rules has been endorsed by Arianna Huffington, Cal Newport (Author of Deep Work), David Carey (Former Global President of Hearst Magazines), Edith Cooper (Board Director of Slack and Etsy and Former Global Head of Human Capital Management of Goldman Sachs), Ginni Rometty (Former Executive Chairman of IBM), Julie Zhuo (Former VP of Product Design of Facebook), Rich Lesser (CEO of BCG), and Ratan Tata (Former Chairman of Tata Group). The Unspoken Rules is now used for employee and manager training and diversity and inclusion at companies such as Aon, GE, IBM, Kirkland & Ellis, Charles River Associates, Abiomed, Invesco, and others. It is also used by programs such as Questbridge, Leadership Enterprise for a Diverse America, Rewriting the Code, ACE Women's Collective, SEO, Africa.com, and others. Harvard Business School has also given Gorick's book to every MBA student to give them an edge in the labor market. Gorick is a career adviser at Harvard College, specializing in coaching first-generation, low-income students. He is also on the faculty at the University of California, Berkeley, where he teaches the unspoken rules of career navigation. Gorick has worked in management consulting at Boston Consulting Group (BCG), investment banking at Credit Suisse, and research with the Managing the Future of Work project at Harvard Business School. He has been featured in Forbes, The Today Show, The New York Times, The Wall Street Journal, BuzzFeed, New York Post, Fast Company, Fortune Magazine, and CNBC. He was named by Thinkers50 as one of 30 thinkers to watch in 2022. Gorick, a first-generation college student, is a graduate of Harvard College and Harvard Business School. Find him at www.gorick.com.

Name: Gorick NgCurrent title: Wall Street Journal Bestselling AuthorCurrent organisation: The Unspoken Rules: Secrets to Starting Your Career Off RightGorick Ng is the Wall Street Journal Bestselling Author of The Unspoken Rules: Secrets to Starting Your Career Off Right, a book published by Harvard Business Review Press. It is a guide to help early-career professionals, especially those form underrepresented backgrounds, navigate the school-to-work transition and ascend to positions of leadership, based on 500+ interviews with professionals across geographies, industries, and job types. The Unspoken Rules is now used for employee and manager training and diversity and inclusion at companies such as Aon, GE, IBM, Kirkland & Ellis, Charles River Associates, Abiomed, Invesco, and others. It is also used by programs such as Questbridge, Leadership Enterprise for a Diverse America, Rewriting the Code, ACE Women's Collective, SEO, Africa.com, and others. Harvard Business School has also given Gorick's book to every MBA student to give them an edge in the labor market. Gorick is a career adviser at Harvard College, specializing in coaching first-generation, low-income students. He has worked in management consulting at Boston Consulting Group (BCG), investment banking at Credit Suisse, and research with the Managing the Future of Work project at Harvard Business School. He has been featured in Forbes, The Today Show, The New York Times, The Wall Street Journal, BuzzFeed, New York Post, Fast Company, and CNBC. Gorick, a first-generation college student, is a graduate of Harvard College and Harvard Business School. Find him at www.gorick.com.Links (for any hyperlinking):- Main website: https://gorick.com/ - Book buy link (USA): https://amzn.to/3hYb6Sa- Book buy link (non-USA): https://tidd.ly/3AstmgI- https://www.linkedin.com/in/gorick - https://twitter.com/GorickNg- https://www.instagram.com/gorick.ng- https://www.facebook.com/GorickNg/ - https://www.tiktok.com/@theunspokenrulesResources mentioned in this episode:Free Download of The Leadership Survival Guide (10 World-Class Leaders Reveal Their Secrets)The Leadership Conversations PodcastThe Jonno White Leadership PodcastThe Leadership Question of the Day PodcastClarity Website7 Questions on Leadership SeriesWe'd Love To Interview YOU In Our 7 Questions On Leadership Series!Subscribe To Clarity's Mailing ListJonno White's eBook Step Up or Step OutJonno White's Book Step Up or Step Out (Amazon)

Jen is a tenured sales leader in the healthcare space who holds a masters in leadership and has been promoted to greater responsibility six different times in her career at Johnson & Johnson and Abiomed. She has been a sales representative, sales trainer, sales manager, sales director, sr. sales director and zone general manager (~Area VP) during her 25 year career. She has worked with and/or led hundreds of different sales professionals in pharma and medical devices, including many who are the best in the business. She is a patient-focused, passionate and driven person with ethical priorities that have shaped organizational operations and the successful career paths of others. Most notably, during over 10 years at Abiomed, she helped to scale the commercial organization from $80m to >$850m in sales leaving a legacy of best practices.     In this podcast Jen will share her insights into: Sales rep to sales management career transition Habits of top sales people Authentic customer focus Minimizing your financial burn rate, considering risk tolerance & passive real estate investing as a path to financial freedom   From a charitable perspective, Jen and her husband, both return AFS exchange students, volunteer with AFS (American Field Service) which sponsors students abroad. She and her family are excited to be hosting their first exchange student for the 22/23 school year. She and her daughter belong to the National Charity League, a mother-daughter volunteer organization, where they are able to contribute to building leadership skills in girls and also volunteer in the community together.     Jennifer can be reached at jenniferaweddell@gmail.com or https://www.linkedin.com/in/jen-weddell-4549b417/   Download our free eBook on “Passively Investing in Real Estate” by going to www.hightechfreedom.com   Subscribe to our newsletter for sales and real estate investing tips by going to www.hightechfreedom.com   Host Contact Information - Chris Freeman LinkedIn - http://linkedin.com/in/chrisfreeman Facebook - https://www.facebook.com/chris.freeman.9461

John Ingram, CCP discusses the Breethe OXY-1 System by ABIOMED a unique, integrated pump lung unit with a built-in mobile O2 concentrator and innovative gas exchange technology.

John Ingram, CCP discusses the Impella 5.5 with SmartAssist Heart Pump Technology by ABIOMED.

New therapeutic approaches require fresh perspectives, and few perspectives were as fresh as Dr. Steven Mickelsen, the developer of a potentially paradigm shifting cardiac ablation treatment – pulse field ablation. Dr. Mickelsen, a high school dropout turned musician, fell deep enough in love with electrophysiology to go back to school, obtain a medical degree, and put his inclination to tinker to work in developing a new type of ablation. In this podcast we'll walk down the path that led Dr. Mickelsen to create Farapulse, the early pioneer in this form of energy that now belongs to Boston Scientific. Dr. Mickelsen left the company a few years ago but he's resumed his work helping Acutus Medical bring their technology to the market. He serves as that company's chief translational science officer. In our second talk, we connect with Dr. Kenneth Stein, senior vice president and CMO of Boston Scientific's cardiac rhythm management business. Dr. Stein allows us to pick up where Farapulse is leaving off, explaining why Boston Scientific bought the company now and what the plans are for the ablation systems, which has CE Mark but still requires FDA approval. Dr. Stein also shares advice for those physicians who may want to join a corporation. We also bring in Medtronic's Rebecca Seidel, president of cardiac Ablation Solutions, and Dr. Robert Kowal, vice president of medical affairs and CMO at the cardiac rhythm and heart failure business. In this excerpt from our recent MedtronicTalks Podcast, Seidel and Dr. Kowal give a quick update on that company's pulse field ablation technology. This week's Newmarker's Newsmakers is delivered by Senior Editor Danielle Kirsh and Associate Editor Sean Whooley including news from Ultrahuman, Johnson & Johnson, ResMed, Abiomed, and Abbott. Subscribe to this podcast on Amazon, Apple, Google and Spotify and other leading podcast apps.

In this week's podcast, Chris Newmarker, executive editor of life sciences, speaks with Laura Rector, Smith + Nephew's vice president of ambulatory surgery centers and digital health, about the company's ARIA care management platform. The system uses 3D imaging, artificial intelligence and other tools to help patients recover more quickly from large joint replacement surgery. What's next for the ortho leader? Meanwhile, Kaila Krum, managing director of Truist Securities, delivers insights on two major stories of the week – the decision by Mike Coyle to leave the CEO post at iRhythm and Medtronic's decision to pull its Heartware HVAD off the shelves. Those two stories topped this week's Newmarker's Newsmakers, which also include items featuring Abbott, Abiomed and the FDA. Subscribe on Google, Amazon, Apple, Spotify, and other leading podcast channels.

Stefan Pilz, Vice President Sales & Marketing EMEA, Abiomed, im Expertengespräch mit Prof. Dr. Andreas Helmut Grün, über die Digitalisierung im Bereich der Behandlung von Coronaren-Herzerkrankungen. Die Digitalisierung ermöglicht hier Behandlungen, die ohne sie nicht denkbar wären. Er erläutert, wie die Herzpumpen von Abiomed bei Hochrisikoeingriffen eingesetzt werden und so sicherstellen, dass Patienten mit Comorbiditäten davon sehr gut profitieren können. Er gibt einen Ausblick auf weitere Digitalisierungsschritten, um die Therapieergebnisse noch deutlicher zu verbessern.

Stefan Pilz, Vice President Sales & Marketing EMEA, Abiomed, im Expertengespräch mit Prof. Dr. Andreas Helmut Grün, über den Einsatz von Echtzeitdatenmanagement beim Einsatz der Herzpumpen und deren Vorteile für das klinische Personal. Mittels eines Platzierungssignals kann die Positionierung der Herzpumpe ideal erfolgen. Mittels Konnekttechnologie und Künstlicher Intelligenz kann die Behandlung des Patienten in Echtzeit überwacht und die Behandlung optimal angepasst werden. Die Digitalisierung ist für die Produkte von abiomed von höchster Bedeutung. Stefan Pilz erläutert dies am Beispiel seiner Impella-Technologie. Grundsätzlich sieht er aber den Bedarf nach einem Mehr an Offenheit für den Einsatz der Digitalisierung im Gesundheitswesen gegeben.

Abiomed, Inc., Q4 2021 Earnings Call, Apr 29, 2021

My guest today, Eric Bell, brings a bunch of inspirational thoughts he gained from his past experiences. He's a former professional triathlete, has a Master's Degree in sports psychology, and, currently, is a medical device representative at Abiomed. We begin our chat with Eric sharing his athletic experiences - from former D1 track athlete to pro triathlete and how he compares it to the industry where he's in now. There are a lot of life-changing scenarios you will want to hear especially if you are thirsty for motivation. Eric, like many of us, is not a superhuman without the ability to ever do wrong. He's gone through struggles and he has one really important piece of advice for when you're struggling in life. This isn't just for prevention from possible issues in the future but a way that will lead to a successful path in the long run. And when we are working on something we want to achieve, we cannot stop failures from happening. Eric mentions to me some ways he believes anyone can be great at what they're doing. He also shares with me his incredible vision that most people need to have. Let's hear more from Eric Bell and reflect on our actions!

On the forefront of every job seeker's mind? How to interview during a global pandemic. Let's introduce you to Madeline Calves. She is a former USMC Communications officer who attended our very first virtual Career Conference in April 2020. Madeline launched her career with Abiomed, a leading medical device company that makes products to help revitalize patients in preparation for important surgical procedures. When we spoke last month, Madeline was completing an intricate training program in preparation for her role as a medical device sales representative. Madeline is excited because she knows that the products she will represent literally change people's lives. Although Madeline has been with Abiomed for less than a year, we wanted to share her thoughts and experiences around virtual interviewing. Her candidate class was the first group of candidates to interview during the pandemic. We thought the topic was still incredibly relevant. Let's flash back to April 2020. Although Madeline had been in the Cameron-Brooks Development and Preparation Program© for 2 years, she said "it was a nervous time." However uncertain at the time, Madeline kept a steady course: "Nothing is ever going to be perfect. It's always going to be hard to transition into the civilian world and you can't make excuses if you know it's the right thing to do." She expands on this idea during our converastion and also shares what she did to help her stand out in the interviews. "It's always going to be hard to transition into the civilian world and you can't make excuses if you know it's the right thing to do." She also gives some great tips on going on "virtual follow up interviews" and the action she took to ensure her success. From there we talk about her first year in Corporate America - the most interesting thing she's learned, her biggest challenges and how she stays engaged in, for the most part, a virtual work environment. As I consider Madeline's experience and consider the hundreds of officers who chose to successfully launch their business career in the midst of a global pandemic, I am convinced that Corporate America is still and will continue to hire committed and prepared military officers. To learn more about turning your JMO leadership skills into a successful transition and business success with Cameron-Brooks, visit our website and check out PCS to Corporate America. You can also follow us on Facebook, Instagram, and LinkedIn.  

In this episode of Medsider Radio, we're catching up with Bruce Shook, the President & CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he's sharing his insights with the Medsider community!In this conversation, we'll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies. But first, here's a bit about Bruce Shook's background:Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University. Before we jump into the conversation, I wanted to mention a few things:First, I'm trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. Here's the deal: I've asked these founders and CEOs to answer a series of questions, which I've converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They're short and sweet, but packed with tons of great insights.I've never tried this before, so let me know what you think!Second, if you're into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. Lastly, here's the link to the full interview if you'd rather read it instead.

Abiomed, Inc. - Q2 2021 Earnings Call - Oct 29, 2020

In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research. How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists? Tune in to listen to this week’s episode of Parallax. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO. Submit your questions to Ankur via: podcast@radcliffe-group.com.

August 4, 2020 - All the top news stories of the day.Support the show (https://www.patreon.com/theoneminutenews)

Abiomed, a company that manufactures heart implant devices, was the first value investing pick for both Carlos and Ashley. They discuss the financial situation and growth potential of the company and the event that put the stock on sale. They also run some numbers to value the company using 10-Cap, Margin of Safety, and Payback Time methods as outlined in Phil Town's book "Rule #1."

Junior Military Officers (JMOs) face numerous obstacles in making a successful transition to business.  They are switching industries (defense to business), companies (Navy, Army, Air Force, etc., to a new company), career fields (unless they are going to a defense contractor or government agency) and locations.  They have to identify companies and positions that value their background, ensure they have openings that sync up with their timelines, line up interviews and hopefully get offers they can evaluate simultaneously. Now, imagine two people doing this simultaneously with the goal of landing a leadership development position with a leading company (in the same city)! This is exactly what dual career military couples making the transition to business have to do.  It is not just twice as complex as a JMO, it is 10 times more complex! It is so complex, in fact, most dual military couples use one of the following two strategies to decrease complexity; however, this can inevitably degrade the quality of their search and number of career choices. Option 1: One of the officers transitions out and finds a position while the other sequences timing to be a bit later and then conducts a job search.  The downside? Usually they are geographically separated for a period of time and the trailing spouse has to do a location specific search which can significantly limit career options.   The trailing spouse does not get to fully explore their business career marketability. Option 2: The couple searches at the same time but without a career search partner that helps them align their options and strategies.  The likelihood of both officers getting offers at the same time and in the same location is very low.  Most likely, one partner will receive an offer while the other is still searching. Or, they run into having to consider offers in different locations.  This causes one or both partners to turn down offers and limit their search to a specific location.  Also, sometimes because they cannot get all of their options lined up at the same time, one or both make significant compromises that degrades the quality of the search. Yet, there is an Options 3: Partner with Cameron-Brooks.  When we partner with dual military couples, we get to know them individually to help their transition to business.  We then match them individually to our client companies based on their unique background and interests.  However, unlike Option 2, we match them with their spouse's/significant other's matches in mind.  We look to create location and company overlaps in their initial interview options.  During the follow-up interview process, we work closely with the couple and their companies. We help them develop strategies to get offers on the table simultaneously so they can make decisions together. Honestly, I have never heard of another resource able to create a successful military couple transition to business strategy other than Cameron-Brooks. It is important to point out that for Option 3 to work, both candidates have to have strong marketability for business and great attitudes about interviewing broadly geographically and career field wise. This creates as many options as possible.  With that, I want to introduce my recent podcast guests, Marquette and Luke Leveque.  They are USNA 2010 graduates and former Navy Submarine Officers.  In fact, Marquette was one of the first female Navy Submarine Officers.  They made the transition from the Navy to Engineering Management positions with Boston Scientific in April 2018.  In fact, they are at the same facility and their children attend daycare there as well! In this podcast, Marquette and Luke share how as a couple they partnered with Cameron-Brooks to land great careers with Boston Scientific in Minnesota. We also had an impressive couple at our April 2020 Conference, Madeline and David Calves who accepted positions with Abiomed and Johnson & Johnson respectively in the Boston area.

Interview with: Cathy Jeon, MD Medical Director, Abiomed

In this edition of Device Week, Medtech Insight's managing editor Marion Webb talks with deputy editor Reed Miller about his recent story on Abiomed's plan to counter unfavorable study outcomes of its Impella heart pump. Medtech Insight articles addressing topics discussed in this episode: AbioMed Launches Plan To Counter Unfavorable Impella Data https://medtech.pharmaintelligence.informa.com/MT126227/Abiomed-Launches-$100M-Plan-To-Counter-Unfavorable-Impella-Data Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs https://medtech.pharmaintelligence.informa.com/MT126231/StartUp-Spotlight-BioIntelliSense-Launches-New-FDACleared-BioSticker-For-Remote-Monitoring-Of-Patien Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger https://medtech.pharmaintelligence.informa.com/MT126216/Knees-Boost-Zimmer-Biomet-Turnaround-Continues-But-FDA-Woes-Linger Boston Scientific Expects Up to $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020 https://medtech.pharmaintelligence.informa.com/MT126214/Boston-Scientific-Expects-Up-To-40M-Impact-In-Q1-From-Coronavirus-Outbreak-1012-Revenue-Increase-For For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR

On this episode of the ECHO Rotor Wash Podcast, we speak with Flight Nurse Ryan Dale from Orlando, FL. Ryan has a fascinating background; as he flies, works in the ICU, and is a rep for Abiomed. He has some absolutely fascinating insight on the care and transport of patients that are on one (or more!) cardiac assist devices. Check it out! Also, let us know what you think of the new Rotor Wash Podcast logo! Don't forget to shop the ECHO Gear Zone!  http://www.echoheliops.org/echo-gear-zone

Earnings season is coming to a close and we’re looking back at what happened at four of our favorite med-tech companies. Inogen and Abiomed both tanked followed their earnings release while ShockWave Medical and Guardant Health both soared. Has the thesis long-term thesis for owning these stocks changed following their second-quarter results? Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

Fitbit cuts guidance after its latest quarterly report and shares hit an all-time low. Aaron Bush analyzes the lone bright spot on Fitbit’s balance sheet, but this may be the beginning of the end.  Shares of data analytics software company Alteryx rise another 10%, while shares of medical device maker Abiomed fall more than 20%. Plus, we discuss the current landscape of esports and potential investments in this growing industry.

Some medical device companies hold such a strong competitive position in their industry that it isn't a stretch to call them a monopoly. In this week's episode, Motley Fool Contributor Brian Feroldi and Industry Focus host Shannon Jones discuss why Intuitive Surgical, Abiomed, and Novocure are three medical device monopolies hiding in plain sight. Stocks Mentioned: ISRG, ABMD, NVCR Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

Jim Dillon, president and CEO of Renal Guard, talks about the company’s decision to create Reprieve Cardiovascular, a start-up focusing on heart failure. Reprieve raised $7 million from outside investors, including Abiomed, and counts Serial Entrepreneur Howard Levin as chief medical officer.

Precision medicines from Loxo Oncology and Blueprint Medicines could take center stage at the most important cancer conference of the year. Also, here’s why Abiomed’s shares have doubled in 2018. (LOXO) (BPMC) (ABMD)

In this episode we explore two very different applications of the Impella® device - a percutaneously-placed temporary ventricular assist device (VAD) sold by Abiomed (no financial disclosures). These VADs work by the use of a micro-axillary pump which is typically placed by interventional cardiologists under fluoroscopy. The inlet of the pump is placed in the ventrical while the outlet rests just above the aortic valve. The post EDECMO 32 – Archimedes Screw: Is Impella the Future of Mechanical Circulatory Support? appeared first on ED ECMO.

Do you think it is possible to create 10 million jobs by 2030? Well, today's guest Kola Masha believes that through Agriculture, Nigeria can create 10 million sustainable jobs to combat the growing unemployment problem in the country. So who is Kola Masha? He is the founder and managing director of Doreo Partners, an impact investing firm that leverages agriculture venture capital to drive youth employment — a critical need in countries such as Nigeria, where half the population is younger than 19 years and youth unemployment exceeds 50 percent. Doreo, invests in early-stage ventures in the agricultural value chain in West Africa, provides strategic advisory services to select clients, including the Gates Foundation and leading global investors in African agriculture. Kola has significant leadership experience on four continents with leading companies such as GE, ABIOMED and Notore Chemicals. At the latter, he was  responsible for raising $130 million in equity and restructuring $360 million in debt at one the region's largest agro-allied firms Notore Foods. A true renaissance man, Kola holds an M.B.A. from the Harvard Business School and a Master's in mechanical engineering from the Massachusetts Institute of Technology. In addition, as a teenager he was the host of a widely syndicated talk show in Nigeria with a record of interviewing 23 guests in one day.   What you will learn ·       Why he returned to Nigeria ·       How he decided to go into the Agriculture sector ·       How his company helps small holder-farmers achieve 5X the yield from their plots ·       How his company has achieved 30X increase in yield over the course of 3 years ·       How his company applies the franchising model similar to McDonalds to Agriculture ·       Talent Management Developing a talented teamLook for employees with a willingness to learn Work with young people who have passion   ·       The challenges of the business ·       The management style of the company ·       How Doreo Partners developed its current fund strategy ·       Advice for entrepreneurs regarding funding new start-ups Focus on learning ·       How to select a business/life partner ·       Criteria for selecting a good business partner  Seek wise counsel   Key Advice ·       Think of what you can do today to create a job for a young person   Words of wisdom   ·       Work hard in your job ·       Learn from both good and bad bosses ·       Push yourself   Contact www.doreopartners.com    

Medical device company Abiomed's CEO Mike Minogue and Stu Randle, CEO of GI Dynamics, sit down with MassDevice.com editor Brad Perriello at the MassDevice Big 100 Roundtable East.

In the kick-off to his new podcast series hosted by SearchSAP, Jon interviews Dan Lubin, Director of Information Technology at Abiomed, about the lessons learned during Abiomed's SAP All-in-One implementation. Hosted by Jon Franke of Search SAP, this podcast is a straight-talking review of the "human side" of Abiomed's SAP implementation. Listen in as Jon Reed asks Dan Lubin how Abiomed managed to implement SAP in 28 weeks, overcoming team burnout and hitting all their milestones. In this thirty minute interview, "the two Jons" and Dan cover key topics such as: - The scope of Abiomed's SAP implementation and how this Danvers, MA company leverages SAP for its international medical device business. - The winning formula Abiomed used to staff its SAP project, and how it combined external consultants with internal team members. - Why offshore resources are important for Abiomed and other midsize companies to fill skills gaps on their SAP project, and how Abiomed used an onshore/offshore mix to meet their "blended rate" cost targets. - Why the typical functional consultant tends to have too narrow a skill set for Abiomed's project and what the skills profile of their ideal functional consultant looks like. The importance of understanding the integration points between modules is emphasized. - How users honestly responded to the new SAP environment and what Abiomed did to ensure that users were on board with a more standardized and structured approach to handling their business processes via SAP. - What the Abiomed team did to overcome burnout and help users get through the most labor-intensive parts of the implementation cycle. - What types of SAP full time employees were recruited to the project and what kinds of expertise they brought with them that rounded out the Abiomed team in areas such as security, validation, and testing. - The "lessons learned" from the SAP implementation and why internal investment in project management is crucial. The results of following (and not following) SAP best practices, the impact of training and why the mundane but vital task of user documentation is of critical importance. - Tips for success: Dan clarifies the difference between knowledge transfer and training and explains how to approach both from the standpoint of managing a budget and making sure that knowledge transfer is an organic result of a well-run implementation. - Would Dan implement SAP again? Dan clarifies a quote Jon cited from SAPPHIRE, challenging Jon on its accuracy, and explains why he would absolutely do the SAP implementation over again and why Abiomed has gained so much from its SAP install and the user community "ecosystem." Dan closes by noting the anticipation for the pending Abiomed European implementation.